Trinity Biotech test gets US clearance

Trinity Biotech said yesterday it received US regulatory clearance to market a diagnostic blood test to detect viruses that cause oral and genital herpes.

The Ireland-based company said the US Food and Drug Administration cleared its Captia test which detects antibodies to Herpes Simplex Virus--1 (HSV-1) and Herpes Simplex Virus-2 (HSV-2). The company said its test, unlike others, can differentiate between the two types of viruses.

Trinity’s shares rose 20c, to $2.92 in morning trading on Nasdaq.